Lazarus 3D
FDA-cleared 3D printed anatomical models enabling surgeons to rehearse on exact patient organ replicas
- CEO / Founder
- Jacques Zaneveld
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $12.09M
- Latest Round
- Unattributed - III
- Key Investors
- Ecliptic Capital, Alliance of Angels, Mentors Fund, Revolution, Capital Factory
Technology & Products
Key Products
Lazarus 3D offers Preoperative Surgical Rehearsal (Pre-Sure) platform, a diagnostic tool for surgical planning that provides surgeons with soft-tissue anatomical models for rehearsal. They create patient-specific replicas of organs like the brain, heart, lungs, and bladder using 3D printing.
Technological Advantage
Proprietary technology for creating realistic organ replicas from patient imaging data
Differentiation
Value Proposition
Enable surgical perfection through exact replicas of patients' organs for pre-operative rehearsal
How They Differentiate
Focus on surgical rehearsal with realistic tissue properties
Market & Competition
Target Customers
Surgeons, hospitals, medical education institutions
Industry Verticals
Healthcare, Medical Devices, Surgical Training
Competitors
Stratasys, 3D Systems, Axial3D, Materialise
Growth & Milestones
Growth Metrics
NIH awards including $371K in 2023, Business Oregon grants
Major Milestones
2014: Founded in Houston TX, FDA clearance for Pre-Sure, $6M seed led by Ecliptic Capital, 2023: $371K NIH award, Relocated to Oregon
Notable Customers
The Cleveland Clinic and over two dozen other hospitals and medical providers.